In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations ...

Healthcare professionals must stop supplying the affected batch, quarantine stock, and return it to suppliers.

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian ...

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova to an untreated control group for the treatment of ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Beacon Therapeutics has exercised its option agreement to license Abeona Therapeutics’ patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases ...

Key Takeaways Lupin's Loteprednol Etabonate Ophthalmic Gel, 0.38% is FDA-approved for treating postoperative ocular inflammation and pain. The gel is bioequivalent to Bausch & Lomb’s Lotemax SM ...